Lawson Health Research Institute

TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) of the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions. The FDA has determined that the Product should follow the De Novo regulatory pathway, and the Company would be required to conduct a clinical study for the De Novo submission for possible approval. “We agree with the FDA feedback and with their recommendations that provides a pathway for the development of the Revive LC POC Lateral Flow Test Kit in the detection of long COVID,” said Michael Frank, CEO of Revive. “We will now discuss the proposed development plan and timelines with potential contract manufacturers.” The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the Product as a potential blood biomarker diagnostic that characterizes long COVID. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine1.Currently, there is no FDA-approved clinical diagnosis of long COVID and it is estimated to occur in at least 10% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. More than 200 symptoms have been identified with impacts on multiple organ systems2 — including fatigue, brain fog, difficulty breathing, and cardiovascular symptoms ranging from chest pain and arrhythmias to sudden cardiac death—but it remains a diagnosis of exclusion with an unknown biological basis3. The Company entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to the intellectual property of novel blood biomarkers that characterize long COVID. The intellectual property includes PCT/CA2023/050145 entitled “Blood Biomarkers in Long-COVID19”; PCT/CA2023/051292 entitled “Biomarkers in Long-COVID19”; and US Provisional Patent Application No. 63/433,425 entitled “Diagnosis and Treatment of Long-COVID”. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com. For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank@revivethera.comWebsite: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2024 ("MD&A"), dated May 28, 2024, which is available on the Company's profile at www.sedarplus.ca. Source: “Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism.” Molecular Medicine 28, 122 (2022). London researchers discover novel method to diagnose long COVID | Lawson Health Research Institute (lawsonresearch.ca)Davis, H.E., McCorkell, L., Vogel, J.M. et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133–146 (2023). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41579-022-00846-2; access https://www-nature-com.libproxy1.nus.edu.sg/articles/s41579-022-00846-2“Proteins In The Blood Hint At Biological Basis Of Long COVID”, Clinical Research News, August 11, 2023, https://www.clinicalresearchnewsonline.com/news/2023/08/11/proteins-in-the-blood-hint-at-biological-basis-of-long-covid

TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce $80,000 research grant has been awarded to Dr. Peter Stirling, PhD, Associate Professor at the University of British Columbia and Senior Scientist at the Terry Fox Laboratory, BC Cancer. This grant supports innovative research aimed at developing bi-functional FEN1 inhibitors that promise to enhance the treatment of glioblastomas by inducing synthetic lethality and stimulating the immune response within tumors. Dr. Stirling's project, titled "Developing new dual function therapies that kill tumour cells and activate immune responses in glioblastomas," targets the aggressive and notoriously treatment-resistant glioblastoma (GBM) tumors. These tumors often suppress local immune responses, making them difficult to treat with conventional chemotherapy alone. The research focuses on a novel chemotherapeutic approach that not only targets tumor cells but also activates the local immune system, potentially overcoming the immune resistance often seen in glioblastomas. The project benefits from the collaboration with experts like Dr. Philip Hieter and Dr. Sheila Singh, who bring specialized knowledge in molecular genetics and clinical practice, respectively. This diverse team will develop therapies that are expected to attack glioblastomas on two fronts: directly killing sensitive tumor cells and recruiting the immune system to tackle resistant cells. Dr. Stirling shared his vision for the project, stating, "Our goal is to transform the treatment landscape for glioblastoma patients by developing therapies that are not only more effective but also harness the body's own immune system to fight cancer. This could significantly improve outcomes for patients facing this challenging diagnosis." Anita Angelini, Vice Chair of Brain Cancer Canada, highlighted the significance of the community and corporate support: "This research is made possible through the generous contributions from Hudson Insurance Group, alongside our dedicated corporate and personal donors. Their support is crucial in bridging the gap between innovative research and tangible treatment advancements." The research integrates cutting-edge technology with clinical insights to address the complex nature of glioblastoma. By focusing on the DNA damage response and its interaction with immune system activation, Dr. Stirling's team is paving the way for novel therapeutic strategies that could substantially impact glioblastoma treatment protocols. This grant follows two other significant research grants issued by Brain Cancer Canada this month, supporting projects led by Dr. Claire Dubois at the Université de Sherbrooke and Dr. Sujoy Banik at London Health Sciences Centre and the Lawson Health Research Institute. Each of these grants is part of Brain Cancer Canada's broader initiative during May's Brain Cancer Awareness Month, known as 'Go Grey in May.' These efforts collectively demonstrate our commitment to advancing research and support for brain cancer patients across Canada. For more details about this ground-breaking research initiative and other efforts by Brain Cancer Canada, please contact sac@braincancercanada.ca Brain Cancer Canada is a national charity dedicated to supporting individuals diagnosed with malignant brain tumors. Through funding innovative research, neurosurgical technology, and advocating for increased options for treatments, Brain Cancer Canada aims to improve survival rates and the quality of life for patients, while providing essential support to their families. Media Contact: Media@braincancercanada.ca

TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce the issuance of an $80,000 grant to support groundbreaking research by Dr. Sujoy Banik and his team at Lawson Health Research Institute in London, Ontario, Canada. The grant will fund a study at London Health Sciences Centre (LHSC) titled “Comparison of intravenous and inhaled anesthetics on brain tumour proliferation: an in-vitro study”. The work aims to assess whether anesthetics used during glioblastoma brain tumour surgery can impact tumour growth, invasion, and metastasis. Given that anesthetics are a crucial part of surgical procedures, understanding their potential influence on brain tumours could significantly affect clinical practices and patient outcomes. Dr. Banik, the principal investigator, a physician anesthesiologist at LHSC and Associate Scientist at Lawson Health Research Institute, explains: “Many patients may receive multiple anesthetics during the course of their treatment for glioblastoma. While exposure to anesthetics is typically short-term, there may be far-reaching implications.” The team hopes findings from this study will provide important insights into the suitability of anesthetics for neuro-anesthesia in patients undergoing brain tumour surgery. Their goal is to better profile the use of anesthetic drugs during brain cancer surgery to improve patient safety and outcomes. Anita Angelini, Vice-Chair of Brain Cancer Canada, highlighted the significance of this research. “We are buoyed by the direction taken by Dr. Banik and his team in this project. This grant reflects our commitment to supporting innovative research that can lead to better outcomes for brain cancer patients," she said. "We believe that this study could provide critical insights into how anesthetics impact brain cancer progression and could ultimately lead to improved surgical practices and patient care.” Dr. Banik also highlights the profound impact of the philanthropic support that is making this work possible, “This grant will help fulfill gaps in research with glioblastoma patients - where every minute spent with family and loved ones is treasured. Our team thanks Brain Cancer Canada, the Andrews Family and Auto|One Group for helping us kickstart our work through the Dwayne Andrews GBM Research Grant.” The grant is the first in a series of four to be issued by Brain Cancer Canada during May, Brain Cancer Awareness Month. This initiative aligns with the organization's commitment to raising awareness and increasing support for brain cancer research. For more information about the study, please contact Brain Cancer Canada at SAC@braincancercanada.ca About Brain Cancer Canada Brain Cancer Canada is a 100% volunteer, national charity that funds research, neurosurgical technologies, and advocates for access to treatments for pediatric and adult brain cancer. For further information, please visit braincancercanada.ca or contact cure@braincancercanada.ca Media Contact:media@braincancercanada.ca